ClinicalTrials.gg
RecruitingNCT07011043Updated Mar 27, 2026

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of Budoprutug in Systemic Lupus Erythematosus, sponsored by Climb Bio, Inc.. Recruiting at 18 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Climb Bio, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine — 4 open to participants now, 9 under way, 6 of them phase 3. Lupus Erythematosus, Systemic · Ukraine.

Planned enrollment
34th of 36
30 · median 331
Started
2025
with 1 other
Phase 1
4 of 36
2 open now
Registered
35th of 36
by date

Among the 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine, this one is the 34th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 1, and was the 35th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lupus Erythematosus, Systemic with a site in Ukraine, or all of them as a file.
02

Study summary

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Read the detailed description

Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b, open-label study will evaluate budoprutug administered as a single intravenous infusion in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will be evaluated as the change in the number of B cells and immunoglobulins (antibodies) in the blood over time following a single infusion.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Lupus
  • SLE
  • Biologics
  • Open-label
  • Monoclonal
  • Anti-CD19
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 65 years at the time of consent.
  2. Diagnosis of SLE according to the 2019 European League Against. Rheumatism and the American College of Rheumatology (ACR) classification criteria.
  3. Active, seropositive disease, with SLEDAI 2K >=8.
  4. Inadequate response to at least 2 therapeutic interventions, including at least one oral or biologic standard-of care therapy.

Exclusion criteria

Exclusion Criteria:

  1. Active neuropsychiatric SLE.
  2. History of inflammatory or diseases including, but not limited to, rheumatoid arthritis, scleroderma, myositis, vasculitis, inflammatory bowel disease, or other conditions that require immune suppressive therapy. Subjects with stable concurrent Sjogren's, asthma, or autoimmune thyroid disease may be considered for participation.
  3. Active systemic infection or history of chronic, recurrent, latent, or recent serious infections.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose Level A

    Drug: Budoprutug

  • Experimental
    Cohort 2: Dose Level B

    Drug: Budoprutug

  • Experimental
    Cohort 3: Dose Level C

    Drug: Budoprutug

  • Experimental
    Cohort 4: Dose Level D

    Drug: Budoprutug

Interventions

  • Single IV dose of study product on Day 1 of study

    Also known as: TNT119

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number of participants experiencing TEAEs, graded per NCI CTCAE v5.0.

    Time frame: Up to Week 24

  2. Incidence of Clinical Laboratory Abnormalities

    Number of participants with clinically significant laboratory abnormalities.

    Time frame: Up to Week 24

  3. Change from Baseline in Systolic Blood Pressure

    Mean change from baseline in systolic blood pressure (mmHg).

    Time frame: Up to Week 24

  4. Change from Baseline in Diastolic Blood Pressure

    Mean change from baseline in diastolic blood pressure (mmHg).

    Time frame: Up to Week 24

  5. Change from Baseline in Heart Rate

    Mean change from baseline in heart rate (bpm).

    Time frame: Up to Week 24

  6. Change from Baseline in Respiratory Rate

    Mean change from baseline in respiratory rate.

    Time frame: Up to Week 24

  7. Change from Baseline in Body Temperature

    Mean change from baseline in body temperature (°C).

    Time frame: Up to Week 24

  8. Change from Baseline in PR Interval

    Mean change from baseline in PR interval (ms).

    Time frame: Up to Week 24

  9. Change from Baseline in QRS Duration

    Mean change from baseline in QRS duration (ms).

    Time frame: Up to Week 24

  10. Change from Baseline in QT Interval

    Mean change from baseline in QT interval (ms).

    Time frame: Up to Week 24

  11. Change from Baseline in QTc Interval

    Mean change from baseline in corrected QT interval (QTc).

    Time frame: Up to Week 24

Secondary outcomes

  1. Area Under the Curve (AUC) of Budoprutug

    Measurement of the area under the drug concentration-time curve.

    Time frame: Up to Week 24

  2. Maximum Observed Plasma Concentration (Cmax)

    Measurement of the maximum observed plasma concentration.

    Time frame: Up to Week 24

  3. Time to Maximum Observed Concentration (Tmax)

    Measurement of the time to maximum observed concentration.

    Time frame: Up to Week 24

  4. Terminal Half-Life (T1/2)

    Measurement of the terminal half-life in days.

    Time frame: Up to Week 24

  5. Apparent Clearance (CL/F) of budoprutug

    Measurement of the apparent clearance in L/hour.

    Time frame: Up to Week 24

  6. Volume of Distribution (Vd)

    Measurement of the volume of distribution in liters.

    Time frame: Up to Week 24

  7. Change from Baseline in Circulating B Cell Count

    Change in absolute number of CD19+ B cells in peripheral blood.

    Time frame: Up to Week 24

  8. Incidence of Anti-Drug Antibodies (ADAs)

    Number of participants with detectable ADAs.

    Time frame: Up to Week 24

  9. ADA Titer Over Time

    Measurement of ADA titer over time.

    Time frame: Up to Week 24

Other outcomes

  1. Change from Baseline in BILAG-2004 Score

    Measurement of change in BILAG-2004 score from baseline.

    Time frame: Up to Week 24

  2. Change from Baseline in SLEDAI-2K Score

    Measurement of change in SLEDAI-2K score from baseline.

    Time frame: Up to Week 24

  3. Change from Baseline in Physician's Global Assessment

    Measurement of change in Physician's Global Assessment score from baseline.

    Time frame: Up to Week 24

  4. Proportion of Participants Achieving SRI-4 Response

    Percentage of participants achieving SRI-4 response.

    Time frame: Up to Week 24

  5. Change from Baseline in Urine Protein Creatinine Ratio (UPCR)

    Measurement of change in UPCR from baseline.

    Time frame: Up to Week 24

  6. Time to Renal Response

    Measurement of time to renal response in weeks.

    Time frame: Up to Week 24

  7. Proportion of Participants with Complete or Partial Renal Response

    Percentage of participants with complete or partial renal response.

    Time frame: Up to Week 24

  8. Change from Baseline in FACIT-Fatigue Score

    Measurement of change in FACIT-Fatigue score from baseline.

    Time frame: Up to Week 24

07

Study locations

18 of 18 sites recruiting
  • Climb Bio Investigative Site #100104
    Allen, Texas 75013, United States
    Recruiting
  • Climb Bio Investigative Site #100101
    San Antonio, Texas 78215, United States
    Recruiting
  • Climb Bio Investigative Site# 359101
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Climb Bio Investigative Site# 359102
    Sofia, 1618, Bulgaria
    Recruiting
  • Climb Bio Investigative Site #995102
    Tbilisi, 0112, Georgia
    Recruiting
  • Climb Bio Investigative Site #995101
    Tbilisi, 0141, Georgia
    Recruiting
  • Climb Bio Investigative Site# 300102
    Exochi, Thessaloniki 57010, Greece
    Recruiting
  • Climb Bio Investigative Site# 300103
    Thessaloniki, Thessaloniki 54642, Greece
    Recruiting
  • Climb Bio Investigative Site #100103
    Caguas, Puerto Rico
    Recruiting
  • Climb Bio Investigative Site# 400101
    Cluj-Napoca, 400006, Romania
    Recruiting
  • Climb Bio Investigative Site# 340101
    Sabadell, Barcelona 08208, Spain
    Recruiting
  • Climb Bio Investigative Site# 340102
    A Coruña, 15006, Spain
    Recruiting
  • Climb Bio Investigative Site #380102
    Ivano-Frankivsk, Ukraine
    Recruiting
  • Climb Bio Investigative Site #380103
    Kyiv, Ukraine
    Recruiting
  • Climb Bio Investigative Site #380106
    Kyiv, Ukraine
    Recruiting
  • Climb Bio Investigative Site #380101
    Ternopil, Ukraine
    Recruiting
  • Climb Bio Investigative Site #380104
    Vinnytsia, Ukraine
    Recruiting
  • Climb Bio Investigative Site #380105
    Vinnytsia, Ukraine
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 21 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
Jun 8, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07011043
Lead sponsor
Climb Bio, Inc.
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jul 10, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Climb Bio Study Director
Contact
clinicaltrials@climbbio.com
+1 866 857 2596
Study Director
study director · Climb Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budoprutug

Start the discussion